北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Moxifloxacin in the treatment of acute bacterial rhinosinusitis: Results of a multicenter, non-interventional study
作者: Zhou, Bing1; Jiang, Xuejun2; Zhai, Lijie3; Xiao, Shuifang4; Wang, Jiadong5; Xiao, Gensheng6; Ruan, Biao7; Liang, Chuanyu8; Ye, Qing9; Hu, Baohua1; Wang, Haibo10
关键词: Effectiveness ; safety ; tolerability
刊名: ACTA OTO-LARYNGOLOGICA
发表日期: 2010-09-01
DOI: 10.3109/00016481003629036
卷: 130, 期:9, 页:1058-1064
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Otorhinolaryngology
研究领域[WOS]: Otorhinolaryngology
英文摘要:

Conclusion: Moxifloxacin was generally well tolerated and highly effective in the treatment of acute bacterial rhinosinusitis (ABS). The incidence of adverse events (AEs) and adverse drug reactions (ADRs) was low. The effectiveness, safety, and tolerability information collected in this study confirm the clinical safety profile of moxifloxacin and its benefit as a treatment option for ABS. Objective: To assess the effectiveness, safety, and tolerability of moxifloxacin under daily life treatment conditions in patients with ABS. Methods: The study was carried out in China between September 2005 and May 2007. Patients with ABS were treated with moxifloxacin tablets 400 mg once daily for a duration that was left to the physician′s discretion. Data were collected on demography, diagnosis of infection, pretreatment, concomitant diseases and medications, moxifloxacin therapy, course of symptoms during investigations, and final assessment of therapy. Results: In all, 578 patients with ABS treated with moxifloxacin were valid for effectiveness analysis. An improvement was observed in 98.8% (n = 571/578) of the patients. Cure was documented in 89.4% (n = 517/578) of the patients. The physicians′ overall tolerability rating was ′very good′ or ′good′ in 92.9% (n = 537/578) of patients. The incidence rates of AEs and ADRs were 1.5% (n = 10/681) and 0.6% (n = 4/681), respectively. No serious AE was reported.

语种: 英语
项目资助者: Bayer Healthcare Company Ltd
WOS记录号: WOS:000282292600014
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/51158
Appears in Collections:北京大学第一临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.China Med Univ, Hosp 1, ENT Dept, Beijing, Peoples R China
2.Peking Univ, Hosp 1, ENT Dept, Beijing, Peoples R China
3.Shanghai Renji Hosp, ENT Dept, Shanghai, Peoples R China
4.Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Key Lab Otolaryngol Head & Neck Surg,Minist Educ, Beijing 100730, Peoples R China
5.Dalian Med Univ, Affiliated Hosp 1, ENT Dept, Dalian, Peoples R China
6.Soochow Univ, Affiliated Hosp 1, ENT Dept, Suzhou, Peoples R China
7.Kunming Med Coll, Affiliated Hosp 1, ENT Dept, Kunming, Peoples R China
8.Sichuan Univ, W China Hosp, ENT Dept, Chengdu, Peoples R China
9.Fujian Prov Hosp, ENT Dept, Fuzhou, Peoples R China
10.Shandong Prov Hosp, ENT Dept, Jinan, Peoples R China

Recommended Citation:
Zhou, Bing,Jiang, Xuejun,Zhai, Lijie,et al. Moxifloxacin in the treatment of acute bacterial rhinosinusitis: Results of a multicenter, non-interventional study[J]. ACTA OTO-LARYNGOLOGICA,2010,130(9):1058-1064.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhou, Bing]'s Articles
[Jiang, Xuejun]'s Articles
[Zhai, Lijie]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhou, Bing]‘s Articles
[Jiang, Xuejun]‘s Articles
[Zhai, Lijie]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace